INTRODUCTION
Chronic non-specific low back pain (CNLBP) not attributable to a recognisable, known specific pathology is common, with an estimated prevalence in developed countries of approximately 23%. 1 CNLBP is a major cause of medical expenses, absenteeism, and disability. There are concerns regarding the benefits and potential harms of medication such as paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids 2 3 for the treatment of chronic back pain, and non-drug treatments including exercise and multidisciplinary and behavioural treatment have been demonstrated to be of benefit. 4 Low-level laser therapy (LLLT) is a light source treatment that may act via nonthermal or photochemical reactions in cells. It includes laser acupuncture (LA), which involves focused irradiation at specific points, most commonly traditional acupuncture points, with a low intensity laser. 5 LLLT for pain relief in medicine remains controversial with claims that apparent efficacy is due to the placebo effect.
Multiple mechanisms for LLLT analgesia may exist. There is experimental evidence suggesting that laser irradiation induces peripheral neural blockade, suppresses central synaptic activity, modulates neurotransmitters, reduces muscle spasm and interstitial oedema, and exerts anti-inflammatory effects. 6 The World Association of Laser Therapy (WALT) has published guidelines for LLLT dosage described in Joules ( J) per point for arthritis and tendinopathy. 7 A number of meta-analyses since 2003 have reported pain relief from LLLT in painful musculoskeletal conditions. [8] [9] [10] In 2008, a Cochrane systematic review of laser therapy focusing on non-specific low back pain (LBP) 11 included seven trials, considered both acute and chronic pain, did not restrict controls to sham laser, and excluded LA trials. At that point, there were insufficient data to draw firm conclusions on the effect of LLLT in LBP. Our objective was to conduct an updated systematic review of the efficacy of LLLT, including LA, for the treatment of CNLBP.
METHODS
This meta-analysis was performed in accordance with the guidelines of the Cochrane Back Review Group (CBRG) 12 and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 13 The study protocol is provided in online supplementary data file appendix A.
Eligibility criteria
Studies were randomised controlled trials (RCTs) with blinded assessment of the outcome. Participants were non-pregnant adults with CNLBP. 1 The primary intervention studied was LLLT, including LA. For the purposes of this review, LA studies were defined as those in which low intensity laser was applied to classical acupuncture points, tender points and/or trigger points, and where acupuncture intent was explicitly stated in the report; other studies were classified as non-acupuncture laser therapy. The comparison intervention needed to be sham laser therapy with similar appearance to the active treatment but without laser irradiation. Studies including co-interventions were allowed if applied equally to both laser and control groups. Crossover studies were excluded.
Outcomes
Primary outcomes were: (1) LBP measured by visual analogue scale (VAS) or numerical pain rating scale (NPRS); and (2) 'global assessment', which represented dichotomous categorical outcomes of overall improvement or satisfaction with the received intervention. These were measured immediately (<1 week posttreatment) and at short-term (1-12 weeks) follow-up.
Secondary outcomes included disability, quantified using the Oswestry Disability Index (ODI) 14 or the Roland-Morris Disability Questionnaire (RMQ), 15 as well as adverse effects, range of movement (ROM) of the back, and pain or global assessment at intermediate (∼6 months) and long-term (∼1 year) follow-up.
Search methods for identification of studies
Electronic databases (MEDLINE, PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials (CENTRAL), Allied and Complementary Medicine Database (AMED), and Physiotherapy Evidence Database (PEDro)) were searched for RCTs of laser therapy or LA for the treatment of chronic LBP in which the control treatment used was sham laser. Publication reference lists were additionally examined to identify any missed studies. We used the Updated Search Strategies for CBRG, 16 which included a generic search for RCTs and controlled clinical trials, combined with a specific search for 'back' conditions. We completed the search by adding terms related to the laser intervention, as detailed in the online supplementary data file appendix B.
Selection of studies, data extraction and management
Papers were initially screened at title and abstract level by one reviewer (GG) who removed duplicate reports and ineligible trials. There was no restriction of full text by language. Potentially eligible papers were reviewed by pairs of reviewers and data extracted independently. Authors were contacted if possible, to clarify further information. We used RevMan 5.3 (Cochrane Collaboration) 17 for data management and statistical analysis.
Assessment of risk of bias in included studies
We adapted the Cochrane Collaboration tool 12 for assessing risk of bias in 12 domains. Paired reviewers categorised domains as 'high', 'low' or 'unclear' risk of bias; disagreements were resolved by consensus. External reviewers assessed bias in one specific trial 18 for which our reviewers were the authors. Trials were considered to be at 'higher risk of bias' if they contained more than six domains of 'high' and 'uncertain' risk.
Measures of treatment effect
For continuous data ( pain intensity, disability, and ROM), treatment effects were expressed as a mean difference (MD) or standardised mean difference (SMD) together with 95% CIs. For global assessment we calculated the risk ratio (RR) and 95% CI. Meta-analysis was used to combine the results of trials using a random-effects model.
Unit of analysis issues
Different pain measurement scales (VAS and NPRS) were converted to a scale of 0-10 cm. In one trial 18 that examined more than one laser dose, in order to avoid 'double counts', we split the sham laser control group into two equally sized groups to allow inclusion of two independent comparisons within the meta-analysis. 19 
Missing data, assessment of heterogeneity and publication bias
We used the RevMan calculator 17 0-40%, 30-60%, and 50-90% were considered to represent 'unimportant', 'moderate', and 'substantial' heterogeneity, respectively. Publication bias was addressed by examination of funnel plots for primary outcomes.
Data synthesis
We conducted meta-analysis for outcomes at immediate and short-term follow-up except where outcomes were reported for two studies or less, in which case results were presented narratively, together with the longer term follow-up. Decisions for conducting subgroup analyses were made at protocol stage based on:
(1) acupuncture/non-acupuncture laser therapy; and (2) laser dosage. A post-hoc decision regarding the cut-off value for laser dose and a subgroup analysis for baseline pain duration was guided by consideration of the review findings. A sensitivity analysis was performed excluding trials considered at 'higher risk of bias'.
Grading the quality of evidence
We followed the CBRG 12 recommendation to adapt the GRADE 20 approach for back reviews with the quality of the evidence based on five domains (limitations of the study design, inconsistency, indirectness, imprecision, and publication bias).
RESULTS

Search results
Electronic searches of databases from inception until August 2014, and screening reference lists, identified 15 studies that satisfied the inclusion criteria (figure 1). Three papers required translation into English from German 21 and Japanese. 22 23 Characteristics of included studies Participants
The selected trials 18 21-34 included 1039 participants at randomisation (table 1) . Participants were mostly recruited into trials from hospitals and rehabilitation clinics, except in the case of four trials 18 21 28 34 that recruited via community newspapers. Some trials did not fully describe details of their inclusion criteria for chronicity 22 23 or specificity. 22 23 31 In trials where the mean baseline duration of pain was reported, this was categorised as 'shorter' 24 26 27 30 (average range 4.6-27 months) or 'longer' 18 21 25 28 29 34 (49 months to 13 years).
Interventions
Five trials were classified as LA studies 18 21 28 31 34 (table 2) . Three of these trials used smaller doses of 0.2-1.1 J/point. 18 28 34 One trial 21 used a 'laser needle' device to deliver 60-180 J/point irradiation, while another 31 used 12 J/point. The remaining 10 trials were classified as nonacupuncture laser therapy studies. Two studies 25 29 used ≤2.8 J/point, while much higher dosages were used in another two trials 26 33 (239 and 1200 J/point, respectively). The remaining six trials used doses in the range of 3-25 J/point. Three trials 24 27 33 used manual scanning to irradiate larger anatomically defined areas as well as irradiation of discrete points. Reporting of laser parameters was incomplete in certain trials and some values were calculated or assumed if authors could not be contacted.
Controls
A variety of methods to achieve sham laser controls were reported including use of the same machine with on/off switch, or use of a separate machine and/or probe. Blinding methods included the use of opaque goggles, as well as a specific laser machine 35 capable of blinding both patient and operator to treatment allocation (table 2). In some trials the description of the masking procedure was unclear 24 26 27 32 or completely absent. 31 Only three studies 18 21 28 statistically analysed the success of the blinding technique used.
Outcomes
Only four trials 18 21 26 28 defined predetermined primary outcomes. The majority of studies reported pain using a VAS; two studies 18 34 used an NPRS. Participant based 'global assessment' was reported as a dichotomised categorical variable including 'condition improved' versus 'same or worse' 18 28 and 'good response' versus 'same or undecided'. 22 23 Two trials only reported an arbitrary level of improvement on a pain scale (eg, >50% reduction of chronic pain on Von Korff Scale 21 or ≥60% reduction pain on VAS scale 32 ). These dichotomous outcomes were combined during meta-analysis to determine the RR of 'global improvement'. The majority of studies that reported disability used ODI; one trial reported only RMQ. 29 Range of back movement was measured as flexion in centimetres (Schober's test) 25-27 30 or in degrees. 24 29 Occurrence of adverse effects was briefly mentioned in five trials 25 26 29 32 34 but quantitative comparisons were only undertaken in three. 18 21 28 Most studies reported immediate and/or short-term outcomes; only three studies 18 28 32 reported outcomes at longer-term follow-up. Figure 2 demonstrates the proportion of studies determined to be low risk for each domain. Under our criteria we found three trials 24 31 33 that we considered to be at 'higher risk of bias'.
Risk of bias in included studies
Primary outcomes Pain
Meta-analysis of data from 653 participants across 10 trials at immediate follow-up indicated a statistically significant reduction in total pain scores in laser versus control groups (WMD (weighted mean difference) −0.79 cm, 95% CI −1.22 to −0.36 cm; I 2 =70%), albeit with substantial heterogeneity (figure 3).
In our subgroup analyses, a significant reduction of pain (laser compared to control) was only seen for the trials in which participants had shorter mean baseline duration (<30 months) of LBP (WMD −1.39 cm, 95% CI −1.71 to −1.07 cm; I 2 =23%). Significant differences between laser and control were also seen in the higher dose trials (>3 J/point) (WMD −1.23 cm, 95% CI 11.61 to −0.84 cm; I 2 =51%) and non-acupuncture trials (WMD −1.17 cm, 95% CI −1.60 to 0.74 cm; I 2 =62%). At short-term follow-up, there were no significant differences and substantial heterogeneity in the total pain score was observed (see six trials, 391 participants; online supplementary data file appendix C). In subgroup analyses we observed a significant reduction of pain (for laser compared to control) with the largest effect seen in higher dose trials and in trials with shorter duration of back pain at baseline (WMD −1.40 cm, 95% CI −1.91 to −0.88 cm; I 2 =0%).
Global assessment
As illustrated in figure 4, pooling of categorical data at immediate follow-up from 416 subjects (five trials) showed a significant effect on global assessment (RR 1.5, 95% CI 1.10 to 2.04; I 2 =65%) in favour of laser treatment (substantial heterogeneity present) with a greater improvement in both non-acupuncture and higher dose subgroups (RR 2.16, 95% CI 1.61 to 2.90; I 2 =0%) with reduced heterogeneity. Pooled data for short-term follow-up showed no significant differences for three included LA trials, two of which used a 'lower' dose (see online supplementary data file appendix D).
Sensitivity analysis
Results were robust to exclusion of trials considered at 'higher risk of bias' with pain differences in favour of laser in the higher dose subgroup at immediate (WMD Original paper 332 −1.5 cm, 95% CI −1.8 to −1.2 cm) and short-term (WMD −1.7cm, 95% CI −2.5 to −1.0 cm) follow-up (see online supplementary data file appendix E). Similar findings were shown in non-acupuncture and 'short duration' subgroups. There were no trials at 'higher risk of bias' 24 31 33 that reported global assessment outcomes.
Secondary outcomes
Intermediate and long-term pain and global assessment Two trials (both low dose LA) reported outcomes at 6 months and at 12 months. They found no significant difference between groups for pain or global assessment at these time periods. One trial 32 that reported less relapse of pain in the laser group at 6 months used an unvalidated outcome.
Disability
Analysis of data from 490 subjects (eight trials) at immediate follow-up found a small reduction in combined ODI score in laser versus control (WMD −2.5%, 95% CI −4.6% to −0.4%; I 2 =47%; see online supplementary data file appendix F). Subgroup analyses showed greater benefit of laser in nonacupuncture trials (WMD −3.5%, 95% CI −6.0% to −1.5%; I 2 =33%), and those applying higher dose treatment and/or including subjects with a shorter duration of back pain (WMD −3.6%, 95% CI −6.1% to −1.1%; I 2 =48%). Combined data from 383 subjects (six trials) at short-term follow-up found no significant difference, but subgroup analyses found greater benefit up to a WMD of −5.9% (95% CI −8.9% to −2.8%; I 2 =64%) in the same groups.
Range of back movement
ROM was measured only in the non-acupuncture trials. 24-27 29 30 One trial 24 found a significant difference of 4°flexion in favour of laser in the short-term.
Adverse effects
Brief reference to the absence of adverse effects was made in six trials. 25 26 29 32-34 Quantitative comparison (including flares of pain and other minor adverse effects) was undertaken in three studies 18 21 28 showed no significant difference between laser and control.
Risk of publication bias
We plotted the effect sizes from trials that reported pain at immediate or short-term follow-up against the inverse of their standard error (see online supplementary data file appendix G). Visual inspection of the funnel plot did not show asymmetry suggestive of 'small study bias'.
Quality of evidence
We reached the conclusion that there was moderate quality evidence (GRADE profile 20 ) that laser therapy reduces pain in the immediate and short term in subjects with CNLBP if pain has been present for Nil Independent assistant operated and covered the coded switch on laser machine determining if laser on or off. Appearance of machine the same regardless of laser output. Success of blinding not reported Entries in bold were not reported/unavailable and were calculated or assumed by reviewers. *'High intensity laser therapy'. Also included manual scanning of fields (2×1400 J). Total dose/session 3000 J. †Laser device allowed simultaneous stimulation of two points. ‡Total treatment duration 20 mins including eight points and manual scanning of standardised field (time differential not reported but assume <150 s per discrete point). Total dose/session 60 J. § a Laser/sham mode set by operating a number on dial. Probe had decoy light/sound device inbuilt. Individualised treatment (average 8-9 points/session) including local and distal GV, BL and GB points and ah shi points. ¶Multi-head device stimulating 10 points simultaneously. **Multi-channel device. Simultaneous stimulation of four points (bilateral BL40 and two ah shi points in lumbar region). † †'Laser needle' fibre-optic cable device. Simultaneous stimulation of eight points (individualised treatment including BL23, BL40, BL60, KI3, GB and ah shi points). Same author previously described 34 laser output tip diameters 2.0 and 0.8 mm (=power density 1 W/cm 2 and 5 W/cm 2 , respectively. ‡ ‡'2 cm grid in painful area' (number of points and irradiation time per point unreported). Spot size given as 0.0015 cm 2 but 1.1 cm 2 with irradiation time 100 s according to Cochrane review. 11 § §Unclear if manual scanning used. ¶ ¶Individualised treatment: local (BL26, ah shi points, GV2) and distal (GV14, BL11, LR3, BL60, LI4, ST36, SP6, PC6, HT7). NR, not reported.
<30 months or if a laser dose of at least 3 J/point is used (see online supplementary data file appendix H). The overall quality of evidence for this outcome was reduced due to limitations in the domain involving risk of bias. For the outcome of global assessment at immediate follow-up, the evidence of benefit of laser therapy was further reduced to low quality due to uncertainty in details of duration and specificity of LBP in trials 22 23 and laser intervention parameters in a trial 32 reporting this outcome.
DISCUSSION
This meta-analysis summarised RCTs that compared the effect of low-level laser with sham controls for the treatment of CNLBP. While combining data from all clinically heterogeneous studies demonstrated a small benefit, subgroup analyses showed larger positive effects of laser on pain, global assessment and disability present up to 12 weeks after treatment, particularly in trials with higher laser dose interventions. The effect size of the pain reduction (over sham) of 1.4 cm in these subgroups approached the minimally important change (MIC) for pain proposed by Ostelo 36 of 1.5 cm. Disability (ODI) reduction was significant in the short term but less than the MIC of 10%. 36 In this review, the mean pain reduction in the placebo laser groups averaged approximately 2.0 cm. The total average pain reduction between baseline and short-term follow-up, representing both non-specific and specific effects of the laser intervention, was about 60%. Our results are consistent with previous findings 8-10 suggesting benefits of low-level laser in a range of painful musculoskeletal conditions including chronic neck pain. In the trials we examined there appeared to be a dose threshold of 3 J/point for benefit of laser. This is higher than the minimal dose suggested by reviews by Baxter 37 (0.5 J/point for myofascial pain) and Chow 38 (0.8 J/point for chronic neck pain), but closer to the dose recommended by WALT 7 (4 J/ point for lumbar spine arthritis). This could be explained by the deeper location of structures in the low back area, requiring a higher laser irradiation dose for penetration. There was no upper dose at which laser appeared not to be effective or caused adverse effects.
Our review also found a relationship between duration of pain and laser effectiveness. This finding is plausible but needs to be explored in further research. Two previous studies examining physical treatment for back pain 39 and acupuncture for chronic pain conditions 40 showed a generally worse outcome for subjects with longer pain duration, but no interaction effect with type of treatment. Acute pain is more likely to resolve spontaneously than chronic pain and, once central sensitisation occurs, a condition may become unresponsive to LLLT.
Most (eight out of 10) non-acupuncture laser therapy trials were positive, that is, they showed a difference between laser and sham groups in primary outcomes; negative trials in this group 25 29 treated participants with a longer duration of pain with a lower dose. Most non-acupuncture laser trials in this review treated relatively few points in the area of pain, although some also irradiated wider areas using a manual scanning technique. Skin surface application of laser results in photon scattering in the underlying volume of tissue, 38 resulting in more widespread biological effects regardless of the intent of the therapist to stimulate acupuncture points, ah shi points or local anatomical structures. Acupuncturists and other laser therapists both irradiate tender points in the region of pain; the absence of positive acupuncture trials in this review could be related to small laser dosage and other factors unrelated to the approach to treatment. We were not able to determine why two higher dose LA trials 21 31 were negative in this review.
Heterogeneity of studies and insufficient data were quoted as reasons for the previous inability to establish firm conclusions on the effect of LLLT for LBP. 11 A strength of our review was the larger number of trials and inclusion of more recent eligible publications since the last such review, as well as exclusion of acute back pain and trials without sham laser controls, thus reducing heterogeneity and allowing the study of specific laser effects. Subgroup analysis was important in explaining the heterogeneity.
A major limitation of this review was related to bias from possible unmasking. Low risk of bias in all blinding domains according to the Cochrane tool was present in only about 60% of trials. In positive trials, the success of blinding was not tested and there were other possible deficiencies in blinding. Subject awareness of thermal sensation in trials with higher power devices is possible, which may potentially have unmasked the patients to treatment allocation. These issues arguably reduce the ability of this review to draw firm conclusions. Inadequate reporting of the characteristics of participants and laser parameters also produced uncertainty.
It is critical that rigorous blinding 35 is instituted in any further clinical trials investigating laser therapy for the treatment of pain. The appropriate laser dose range for specific body regions (as recommended by WALT) should be followed, and full and explicit description of the laser parameters, 5 treatment regimen, and baseline characteristics of the participants is important. Future studies may also establish the role of other components of the intervention such as the number and/or location of points, frequency/ duration of treatment, and the effect of longer-term follow-up on outcomes.
Our meta-analysis suggests that LLLT, when used by itself or in combination with other modalities, may achieve a useful reduction in pain for up to 3 months in CNLBP with few adverse effects. However, we would recommend a degree of caution before widespread implementation, until our results can be confirmed by further rigorously blinded trials using adequate laser doses.
Summary points
▸ This updated systematic review examined the effectiveness of low-level laser therapy compared to sham laser in the treatment of chronic non-specific low back pain. ▸ There was substantial clinical heterogeneity present between the 15 included trials, related to differences in both participant characteristics and laser interventions. ▸ Meta-analysis showed a clinically important pain reduction in laser versus sham lasting up to 12 weeks post-completion of treatment (WMD −1.40 cm, 95% CI −1.91 to −0.88 cm). ▸ Pain reduction occurred in subgroups with nonacupuncture laser interventions, laser dosage ≥3 J per point, and in participants with a shorter duration of baseline pain (30 months). ▸ Further trials using strict masking and adequate laser doses are needed to ensure that the apparent benefits of laser are not due to bias related to unblinding of participants. 
